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days of absenteeism from work were 3.3. Resource consumption
was a little higher in the unsatisfactory glycemic control group
(p < 0.05). This higher consumption was also associated with the
patient’s insulinization and type of diabetes, specially the absen-
teeism from work (p < 0.05); the highest value (12.7 days) was
reported by T1DM patients with unsatisﬁed glycemic control.
CONCLUSIONS: Diabetes involves a large burden to society in
terms of resource consumption and labour absenteeism. Unsat-
isfactory glycemic control and patient’s insulinization was also
associated with a higher resource consumption.
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OBJECTIVES: Determine the direct cost of treatment for
patients with Type II Diabetes (T2D) in Greece. METHODS: In
order to deﬁne the patient management model, a 2-step method-
ology was implemented. First, a questionnaire-based survey was
conducted in a random sample of 51 physicians specializing in
the treatment of T2D, geographically distributed according to
the total population of T2D patients in Greece. Participating
physicians were asked to review their patient records before
completing the questions regarding patient resource utilization
and other speciﬁc treatment parameters. As a second step, the
survey ﬁndings were reviewed by an expert consensus panel for
validation and ﬁnal deﬁnition of the data for the analysis.
Patients were categorized as (a) regulated (i.e. maintaining
glucose levels within therapeutic range for a 1-year period) and
(b) non-regulated. Cost analysis was based on estimation of
1-year direct cost of treatment (physician consultations,
laboratory/diagnostic tests and pharmacotherapy—insulin and
oral hypoglycemic agents), based on 2007 private sector fees and
prices, in Euros. Hospitalization costs were not included.
RESULTS: Average direct cost for regulated patients (46% of
total T2D patient population) was estimated at €983/year, while
for the non-regulated (54%) it was signiﬁcantly higher, at €1570.
For regulated patients, laboratory/diagnostic tests accounted for
43.6%, physician consultations for 21.8% and pharmacotherapy
for 34.6% of the total average cost, whereas for the non-
regulated the respective values were 45.9%, 26% and 28.1%.
Weighted average patient cost was calculated at €1300/year,
resulting in a total cost of approximately 1 billion Euros/year for
the estimated 780,000 T2D patients in Greece. CONCLU-
SIONS: Although not including the cost of hospitalizations and
complications, which account for approximately 2/3 of the total
patient cost, as reported in the literature, this study demonstrated
the importance of blood glucose control/regulation, not only
from the clinical but from the economic perspective as well.
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OBJECTIVES: Describe, in usual care, health care resource uti-
lization and costs associated before and during the ﬁrst 6 months
of insulin therapy in patients with type 2 diabetes (T2D).
METHODS: Pan-european observational study. Here results for
France are reported. The direct costs of diabetes care include
costs of visits to health care professionals, antidiabetic medica-
tions, glucose testing and hospitalizations linked to diabetes.
Costs were calculated by collecting individual resource use and
assigning local units costs (2006). RESULTS: Of the 177 T2D
patients initiated with insulin, 152 (85.9%) patients were fol-
lowed to 6 months. Enrolled patients (male 57%) had mean age
of 64.8 years 11.3 (SD) and mean BMI of 29.4 kg/m2 6.2
(SD). They had been diagnosed with diabetes 13.0  8.1 (SD)
years ago and had a mean HbA1C at insulin initiation of 9.6%
1.9 (SD). Long/intermediate insulin only was the most common
therapy initiated (80.8% of patients). 50.3% of patients were
hospitalized for insulin initiation. At 6 months 86.2% of patients
were taking oral antidiabetics; metformine and sulfamide
(31.6%), metformine only (14.5%) or sulfamide only (13.2%).
During the 6 month follow up, 81.6% of patients visited a
general practitioner, 71.1% a diabetologist and 14.5% had a
hospital admission due to diabetes (median stay = 3.0 days). The
median number of visits to diabetologists was 1 in the 6 months
prior to insulin initiation and 2 in the 6 months following initia-
tion, the median costs of diabetes speciﬁc specialist care increased
from 41 € to 83 €. Median total costs (interquartile range) for the
6 months prior to as well as after insulin initiation were €647
(421–1373) and €805 (579–1213), respectively. CONCLU-
SIONS: Half of the patients were hospitalized for insulin initia-
tion. The median cost of diabetes care increased in the 6 months
following insulin initiation.
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OBJECTIVES: Diabetes is a public health issue of signiﬁcant
economic importance because of the chronic nature and the
serious complications associated with long disease duration. The
aim of the study was to describe the direct medical cost for
average patient with type 2 diabetes and for whole population
of diabetics in Czech Republic using ″bottom-up“ costing
approach. METHODS: The data collection was arranged in
ambulatory diabetologists by speciﬁc questionnaire. Data were
collected between October nad December 2007 and covered a
minimum period of 6 months, retrospectively. Estimates of health
care utilisation and costs were projected for a 12-month period.
The overall direct health care costs were calculated by multiply-
ing the quantities of the resource used with the unit reimburse-
ment of each resource by insurance company. RESULTS: During
the collection phase of the study 495 patient records were gained.
The average HbA1C values were 6.0%, body mass index (BMI)
was 29.9 for men and 31.1 for women and the average blood
presure was 141/80 mm Hg. At least one microvascular compli-
cation is present in 49.29% and at least one macrovascular
complication in 44.24% of type 2 diabetic patients. According to
the type of treatment 10.51% of patents were treated with diet
and exercise, 49.9% were on oral antidiabetic drugs and 39.6%
were on insulin therapy. Hypolipidemic drugs were present in
63.4% and antihypertensive drugs in 82.8% of patients. The
majority of diabetic patients visited ambulatory diabetologist
(98.99%, mean number of visits 2.3), general practitioner
(91.31%, mean number of visits 3) or other ambulatory special-
ist (75.4%), mainly ophthalmology, cardiology or neurology in
last 6 month. In the same time period 16.16% of patients were
hospitalized with average length of stay 13.68 days (1.2 days in
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intensive care unit bed). The mean direct medical expenditures
for one patient is 25,858 CZK (€1,034) per year. CONCLU-
SIONS: Based on data from Institute of Health Information and
Statistics of the Czech Republic in 2006 there were 678 760 type
2 diabetic patients in our country. It it roughly 17.5 bilion CZK
(€0.7 bil) per year, counting approximately 20% of total health
care spending in Czech Republic.
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OBJECTIVES: To estimate the annual medical costs attributable
to obesity in diabetic patients. METHODS: This cross-sectional
analysis was based on the 2001–2005 Medical Expenditure Panel
Survey data, a nationally representative sample of the U.S. non-
institutionalized population. A total of 4880 diabetic patients
were identiﬁed based on the ICD-9-CM code:250 after excluding
patients with pregnancy, malignancy, kidney dialysis, immuno-
deﬁciency, or >75years old. Diabetic patients were classiﬁed as
normal (body mass index(BMI):18.5–<25), overweight(BMI:25–
<30), or obese(BMI:30). Medical costs included costs associ-
ated with any treatments except dental problems and injuries.
The parameters for obese patients were estimated using a gener-
alized linear model with a log link function and a gamma distri-
bution after adjusting for the demographic variables. The mean
medical cost was predicted for normal-weight patients using the
parameters estimated from the obese patients. The difference
between the predicted and the observed costs in normal weight
patients was the medical costs attributable to obesity. All costs
were converted to 2005 U.S. dollars using price indices. Data
were analyzed using SAS and SUDAAN. RESULTS: The age-
adjusted prevalence of the study diabetic patients was 2.1% in
normal-weight, 3.9% in overweight, and 9.7% in obese patients
respectively. The average attributable costs to obesity in diabetic
patients were $1,527 (95%CI:$318–$2736). The average attrib-
utable costs to obesity increased as patients became older ($794
for aged 18–50, $1636 for aged 51–64, and $2044 for aged
65–74) and were higher in women ($2679) than men ($139), and
in private insurance ($2185) compared to public insurance
($591). CONCLUSIONS: The prevalence of diabetes in obese
people was approximately ﬁve times higher than in normal-
weight people. The medical costs for obese patients with diabetes
were signiﬁcantly higher than in normal weight patients. The
effective public health intervention aimed at controlling weight in
diabetic patients is recommended to reduce the extra economic
burden of obesity.
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OBJECTIVES: To estimate and compare the economic implica-
tions of insulin glargine (GLAR) and detemir (DET) therapy
initiation in a population with type 2 diabetes mellitus (T2DM)
with a one year time horizon, from major insurers perspectives in
Argentina (union-based and private HMOs). METHODS: Clini-
cal and efﬁcacy parameters and their distributions were based on
Rosenstock’s article (2008), a 52-week randomized treat-to-
target trial which compared clinical outcomes following supple-
mentation of oral glucose-lowering drugs with basal insulin
analogues, DET and GLAR, in T2DM patients. Resource use and
cost values, as well as their distributions, were obtained from
Argentinean published literature, tariffs, databases, experts’
opinion and the international literature. Costs are expressed in
local currency, year 2008 (exchange rate 1€ = 4.79ARG$). Vari-
ability was incorporated in insulin, needles and strips costs,
proportion of DET patients with once daily injection and GLAR
and DET dose per kilogram. Probabilistic sensitivity analysis
(PSA) was carried out based on Monte Carlo simulations with
10,000 iterations. Linear regression analysis was carried out in
order to gauge the relative inﬂuence on the results related to the
uncertainty around each parameter. RESULTS: Annual mean
cost was $2630 for GLAR and $4,092 for DET, implying a 36%
(95%CI 33.2%; 37.9%) total cost saving with GLAR ($1462). A
total of 82.7% of this difference was explained by the lower
average daily dose requirement with GLAR (GLAR 26 UI vs.
DET 42 UI). Savings in test strips, and needles explained 10.2%
and 7.1% of the total difference. In the regression analysis, the
most important parameters explaining variability in total cost
savings were the proportion of DET patients requiring twice
daily injections followed by the insulin dose per patient. CON-
CLUSIONS: In Argentina, Insulin Glargine was associated with
a cost saving of more than one third compared to the use of
Insulin Detemir. Sensitivity analyses conﬁrmed the robustness of
this result.
PDB34
MONITORING OFTREATMENT COSTS AFTER
REIMBURSEMENT DECISION: SOMATOSTATIN ANALOGUES
FOR ACROMEGALY
Valentim J1, Passos V2, Calabró A3
1University of São Paulo, São Paulo, SP, Brazil, 2Novartis
Pharmaceuticals, East Hanover, NJ, USA, 3Novartis Biociências SA, São
Paulo, SP, Brazil
OBJECTIVES: To compare the economic impact of the treatment
of acromegaly with two different somatostatin analogues in
Brazil, after the decision of reimbursement of the therapeutic
class by the Brazilian Public Health Care System (SUS) in 2002.
METHODS: Acromegaly treatment cost estimation was based
on secondary data and on a decision analytical model developed
from the Brazilian Public Health Care System Clinical Guideline
for Acromegaly. The strategies of using somatostatin analogues
in depot presentations (octreotide LAR or lanreotide SR) were
compared. The model followed a hypothetical cohort of 276
patients diagnosed with acromegaly for two years. Costing
included direct medical costs, composed by drugs, consultations,
monitoring tests, radiotherapy and hospitalisation, under the
Brazilian Public Health Care System perspective. Data were
extracted from national and international literature, and from
administrative ofﬁcial databases (Ambulatory Information
System, Hospital Information System, Mortality Information
System). Costs are reported in 2005 Reais (R$) and Euros (€).
Ofﬁcial exchange rate was used for currency conversion (2.77
BRL = 1 EUR, Brazilian Central Bank). Sensitivity analysis was
conducted. RESULTS: Octreotide LAR treatment strategy pre-
sented net savings of R$10,448,324 (€3,771,958) to the Brazilian
Public Health Care System when compared to lanreotide SR
treatment strategy in a period of two years. Average annual cost
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